Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis
出版年份 2018 全文链接
标题
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis
作者
关键词
Pancreatic cancer, Meta-analysis, Randomized controlled trial, Second-line chemotherapy, Salvage chemotherapy, Post-progression survival
出版物
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-03-23
DOI
10.1007/s10637-018-0589-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
- (2018) Herbert Hurwitz et al. INVESTIGATIONAL NEW DRUGS
- Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
- (2017) Makoto Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
- (2017) Angélique Vienot et al. JNCI-Journal of the National Cancer Institute
- Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care
- (2017) Huaqiang Ouyang et al. PANCREATOLOGY
- Biliary drainage improves the predictive value of modified Glasgow Prognostic Scores in inoperable pancreatic cancer
- (2017) Chikara Iino et al. PLoS One
- Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
- (2017) Angélique Vienot et al. JNCI-Journal of the National Cancer Institute
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer.
- (2017) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Second-Line Treatment in Pancreatic Cancer Patients
- (2016) Marianne Sinn et al. PANCREAS
- A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2015) M. Ueno et al. ANNALS OF ONCOLOGY
- Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
- (2015) S Ohkawa et al. BRITISH JOURNAL OF CANCER
- Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
- (2015) Takeshi Terashima et al. HEPATOLOGY RESEARCH
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival
- (2014) Akiyoshi Kasuga et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study
- (2014) F. Ge et al. ONCOLOGIST
- Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer
- (2013) Hisato Kawakami et al. EUROPEAN JOURNAL OF CANCER
- S-1 plus CIK as second-line treatment for advanced pancreatic cancer
- (2013) Meng Wang et al. MEDICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
- (2012) F. Petrelli et al. ANNALS OF ONCOLOGY
- Postprogression Survival in Patients With Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy
- (2012) Hidetoshi Hayashi et al. Clinical Lung Cancer
- Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
- (2011) H. Hayashi et al. ANNALS OF ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- Definition and classification of cancer cachexia: an international consensus
- (2011) Kenneth Fearon et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- oral presentations
- (2010) ANNALS OF ONCOLOGY
- Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
- (2010) Everardo D. Saad et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now